NCT00967681已完成3 期
Efficacy and Safety of Nutritional Supplement ONCOXIN in Patients With Breast Fibrocystic Disease
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Catalysis SL
- 入组人数
- 200
- 试验地点
- 2
- 主要终点
- The ultrasonographic improvement at 24 weeks (end of the treatment)
研究概览
简要总结
The purpose of the study is to evaluate whether Oncoxin, a nutritional supplement, improves the clinical and ultrasonographic results in comparison with placebo during 24 weeks of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with clinical and ultrasonographic confirmation of breast fibrocystic disease.
- •Patients older than 20 years.
- •Female patients.
- •Informed consent.
排除标准
- •Presents of another disease not well controlled.
- •Pregnant women or lactating.
- •Patient which are receiving another products from other investigations trials.
结局指标
主要结局
The ultrasonographic improvement at 24 weeks (end of the treatment)
时间窗: 24 weeks
Adverse effects at 24 weeks (end of the treatment)
时间窗: 24 weeks
次要结局
- Lesion size according clinical measurement at 24 weeks (end of the treatment)(24 weeks)
- Pain according patient examination at 24 weeks (end of the treatment)(24 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial CancerCarcinomaOvarian NeoplasmEndocrine Gland NeoplasmUrogenital NeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsEndocrine System DiseasesGonadal DisordersGenital Neoplasm, FemaleNeoplasms, Glandular and EpithelialNCT03562897Catalysis SL40
尚未招募
2 期
Oncoxin-Viusid/Stomach and gastric esophagus union cancer / Adults / Phase IIcancer of the stomach and gastric esophagus union.Stomach NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsEsophageal NeoplasmsHead and Neck NeoplasmsGastrointestinal DiseasesDigestive System DiseasesEsophageal DiseasesStomach DiseasesEsophagogastric JunctionRPCEC00000272aboratorios Catalysis, S45
已完成
2 期
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic AdenocarcinomaAdenocarcinoma of the PancreasAdvanced CancerDigestive System NeoplasmsPancreatic NeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic CancerEndocrine System DiseasesPancreatic DiseasesNCT03717298Catalysis SL30
尚未招募
2 期
Oncoxin-Viusid-Advanced or metastatic ovarian epithelial cancer-Adult women-Phase IIEpithelial advanced or metastatic ovarian cancerCarcinomaOvarian NeoplasmsEndocrine Gland NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms, Glandular and EpithelialOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsEndocrine System DiseasesGonadal DisordersRPCEC00000269Catalysis Laboratory S.L.40
已完成
2 期
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal AdenocarcinomaColorectal NeoplasmIntestinal NeoplasmsGastrointestinal NeoplasmsRectal DiseasesColonic DiseasesIntestinal DiseaseGastrointestinal DiseaseDigestive System NeoplasmDigestive System DiseaseNCT03559543Catalysis SL40